Page 41 - JCTR-11-3
P. 41
Journal of Clinical and
Translational Research Immunogenicity and safety of flu vaccines
Writing – review & editing: Lei Wang, Hongbo Zhang, Ze and the associated vaccines development in China: A review.
Chen Vaccines (Basel). 2022;10:1873.
doi: 10.3390/vaccines10111873
Ethics approval and consent to participate
9. Wang Y, Zhang Y, Wu H, et al. Safety and immunogenicity of
Not applicable. a quadrivalent inactivated subunit non-adjuvanted influenza
vaccine: A randomized, double-blind, active-controlled
Consent for publication phase 1 clinical trial. Vaccine. 2021;39:3871-3878.
Not applicable. doi: 10.1016/j.vaccine.2021.05.070
Availability of data 10. Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza
vaccines. Hum Vaccin Immunother. 2018;14:550-564.
Data are available from the corresponding author on doi: 10.1080/21645515.2017.1415684
reasonable request.
11. Huang X, Feng L, Du X, et al. Guidelines for influenza
References vaccination among healthcare workers in China. Chin J
Infect Control. 2023;22:871-885.
1. National Immunization Advisory Committee (NIAC)
Technical Working Group (TWG), Influenza Vaccination 12. Feng LZ, Jiang HY, Yi J, et al. Introduction and implications
TWG. Technical guidelines for seasonal influenza of WHO position paper: Vaccines against influenza, May
vaccination in China (2022-2023). Zhonghua Liu Xing Bing 2022. Zhonghua Yi Xue Za Zhi. 2022;102:2315-2318.
Xue Za Zhi. 2022;43:1515-1544. doi: 10.3760/cma.j.cn112137-20220518-01090
doi: 10.3760/cma.j.cn112338-20220825-00734 13. Nct. Clinical Study to Evaluate Safety, Immunogenicity
2. Trombetta CM, Kistner O, Montomoli E, Viviani S, of Investigational Flu Vaccine Compared to an Approved
Marchi S. Influenza viruses and vaccines: The role of Flu Vaccine (QIV) in Children Previously Vaccinated in
vaccine effectiveness studies for evaluation of the benefits of Trial V118_05; 2014. Available from: https://clinicaltrials.
influenza vaccines. Vaccines (Basel). 2022;10:714. gov/study/NCT02255409?cond=Clinical%20Study%20
to%20Evaluate%20Safety,%20Immunogenicity%20
doi: 10.3390/vaccines10050714 of%20%20Investigational%20Flu%20Vaccine%20
3. Wang S, Dong J, Chai W, et al. Immunogenicity of a Compared%20to%20an%20Approved%20Flu%20%20
monovalent 2009 influenza A (H1N1) vaccine in infants: Vaccine%20(QIV)%20in%20Children%20Previously%20
Randomized, observer-masked, single-center clinical study. Vaccinated%20in%20Trial%20%20V118_05&rank=1
Springerplus. 2014;3:397.
14. Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF,
doi: 10.1186/2193-1801-3-397 Osterhaus A. Influenza vaccines: Successes and continuing
challenges. J Infect Dis. 2021;224:S405-S419.
4. Feng L, Yang P, Zhang T, et al. Technical guidelines for
the application of seasonal influenza vaccine in China doi: 10.1093/infdis/jiab269
(2014-2015). Hum Vaccin Immunother. 2015;11:2077-2101.
15. Sullivan SG, Price OH, Regan AK. Burden, effectiveness
doi: 10.1080/21645515.2015.1027470 and safety of influenza vaccines in elderly, paediatric and
pregnant populations. Ther Adv Vaccines Immunother.
5. National Immunization Advisory Committee (NIAC)
Technical Working Group (TWG), Influenza Vaccination 2019;7.
TWG. Technical guidelines for seasonal influenza doi: 10.1177/2515135519826481
vaccination in China (2021-2022). Zhonghua Liu Xing Bing 16. Grohskopf LA, Blanton LH, Ferdinands JM, et al.
Xue Za Zhi. 2021;42:1722-1749.
Prevention and control of seasonal influenza with
doi: 10.3760/cma.j.cn112338-20210913-00732 vaccines: Recommendations of the advisory committee on
immunization practices - United States, 2022-23 influenza
6. 2023-2024 CDC flu Vaccination Recommendations
Adopted. 2023. Available from: https://www.cdc.gov/flu/ season. MMWR Recomm Rep. 2022;71:1-28.
spotlights/2022-2023/flu-vaccination-recommendations- doi: 10.15585/mmwr.rr7101a1
adopted.htm
17. Ainslie KEC, Haber M, Orenstein WA. Challenges in
7. Sekiya T, Ohno M, Nomura N, et al. Selecting and using the estimating influenza vaccine effectiveness. Expert Rev
appropriate influenza vaccine for each individual. Viruses. Vaccines. 2019;18:615-628.
2021;13:971.
doi: 10.1080/14760584.2019.1622419
doi: 10.3390/v13060971
18. Yang Z, Wang S, Li W, et al. The long-term immunogenicity
8. Zhang J, Nian X, Li X, et al. The epidemiology of influenza of an inactivated split-virion 2009 pandemic influenza A
Volume 11 Issue 3 (2025) 35 doi: 10.36922/JCTR025060006

